APA (7th ed.) Citation

V, Y., DN, B., JD, B., SG, L., D, M., J, P., . . . AA, V. (2012). Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study. Autoimmune diseases, 2012, 954739. https://doi.org/10.1155/2012/954739

Chicago Style (17th ed.) Citation

V, Yadav, et al. "Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study." Autoimmune Diseases 2012 (2012): 954739. https://doi.org/10.1155/2012/954739.

MLA (9th ed.) Citation

V, Yadav, et al. "Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study." Autoimmune Diseases, vol. 2012, 2012, p. 954739, https://doi.org/10.1155/2012/954739.